Effects of levcromakalim in patients with migraine aura without headache: An experimental study

Andreas Vinther Thomsen,Mohammad Al-Mahdi Al-Karagholi,Anders Hougaard,Sisse Rye Ostrowski,Messoud Ashina
DOI: https://doi.org/10.1177/03331024241274366
2024-08-22
Cephalalgia
Abstract:Cephalalgia, Volume 44, Issue 8, August 2024. Background/HypothesisLevcromakalim has previously been shown to induce attacks of migraine with aura in certain individuals. In this study, we tested the migraine-inducing effect of levcromakalim in a cohort of participants with migraine aura without headache.MethodsIn a double-blind, randomized, placebo-controlled cross-over study, eight adult participants with migraine with aura received intravenous infusions of levcromakalim and saline. Headache, aura and associated symptoms were evaluated for 24 h following administration of the study drug. The primary endpoint was occurrence of migraine-like attacks with or without aura in the 24-h observation period.ResultsFive participants (62.5%) developed migraine of any type following levcromakalim compared with three participants (37.5%) following placebo. No participants developed aura following levcromakalim.Conclusion/InterpretationOur findings suggest that the aura-inducing effect of levcromakalim is likely not based on direct induction of cortical spreading depression but may involve activation of the trigeminovascular system. This hypothesis should be further explored in future studies.ClinicalTrials.gov identifierNCT04905654
neurosciences,clinical neurology
What problem does this paper attempt to address?